(Q38116570)

29 August 2017

title

Protein kinase C inhibitors: a patent review (2008 - 2009). (English)

1 reference

29 August 2017

M Elizabeth Sobhia

1

1 reference

29 August 2017

Baljinder K Grewal

2

1 reference

29 August 2017

Stanly Paul Ml

3

1 reference

29 August 2017

Jigneshkumar Patel

4

1 reference

29 August 2017

Amandeep Kaur

5

1 reference

29 August 2017

Thongtinlal Haokip

6

1 reference

29 August 2017

Alekhya Kokkula

7

1 reference

29 August 2017

language of work or name

English

0 references

publication date

25 June 2013

1 reference

Expert Opinion on Therapeutic Patents

29 August 2017

published in

1 reference

29 August 2017

volume

23

1 reference

29 August 2017

issue

10

1 reference

29 August 2017

page(s)

1297-1315

1 reference

Protein kinase C: structural and spatial regulation by phosphorylation, cofactors, and macromolecular interactions

29 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.805205

Synthetic diacylglycerols (DAG) and DAG-lactones as activators of protein kinase C (PK-C).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.805205

Platelet-derived growth factor and lysophosphatidic acid inhibit growth hormone binding and signaling via a protein kinase C-dependent pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.805205

Phorbol esters: structure, biological activity, and toxicity in animals.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.805205

Effects of protein kinase C activators on phorbol ester-sensitive and -resistant EL4 thymoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.805205

Cell cycle and biochemical effects of PD 0183812. A potent inhibitor of the cyclin D-dependent kinases CDK4 and CDK6.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.805205

The DNA repair complex DNA-PK, a pharmacological target in cancer chemotherapy and radiotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.805205

Protein kinase C βII in diabetic complications: survey of structural, biological and computational studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.805205

Regulation of the ABC kinases by phosphorylation: protein kinase C as a paradigm

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.805205

A novel mycothiol-dependent detoxification pathway in mycobacteria involving mycothiol S-conjugate amidase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.805205

Tissue and cellular distribution of the extended family of protein kinase C isoenzymes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.805205

Isoform-selectivity of PKC inhibitors acting at the regulatory and catalytic domain of mammalian PKC-alpha, -betaI, -delta, -eta and -zeta

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.805205

Requirement for protein kinase C in reactive oxygen species-induced apoptosis of vascular smooth muscle cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.805205

Staurosporine induces necroptotic cell death under caspase-compromised conditions in U937 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.805205

Discovery of 3-(1H-indol-3-yl)-4-[2-(4-methylpiperazin-1-yl)quinazolin-4-yl]pyrrole-2,5-dione (AEB071), a potent and selective inhibitor of protein kinase C isotypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.805205

6-Hydroxydopamine upregulates iron regulatory protein 1 by activating certain protein kinase C isoforms in the dopaminergic MES23.5 cell line

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.805205

Rottlerin, a novel protein kinase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.805205

PKC-alpha inhibitor MT477 slows tumor growth with minimal toxicity in in vivo model of non-Ras-mutated cancer via induction of apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.805205

Protein kinase C inhibitors as novel anticancer drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.805205

Selective protein kinase C inhibitors and their applications

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.805205

Inhibition of protein kinase C by the tyrosine kinase inhibitor erbstatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.805205

Enzastaurin (LY317615), a protein kinase C beta selective inhibitor, enhances antiangiogenic effect of radiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.805205

Bryostatin-1: a novel PKC inhibitor in clinical development

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.805205

Protein kinase C is inhibited by bisphosphonates in prostate cancer PC-3 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.805205

Clinical safety of the selective PKC-beta inhibitor, ruboxistaurin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.805205

Structure and functional relationships of Hsp90.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.805205

Selectivity and therapeutic inhibition of kinases: to be or not to be?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.805205

Opportunities and challenges in the development of kinase inhibitor therapy for cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.805205

A phase I trial of daily oral 4'- N -benzoyl-staurosporine in combination with protracted continuous infusion 5-fluorouracil in patients with advanced solid malignancies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.805205

A phase II study of UCN-01 in combination with irinotecan in patients with metastatic triple negative breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.805205

A Phase 1 study of UCN-01 in combination with irinotecan in patients with resistant solid tumor malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.805205

Phase I and pharmacokinetic study of PKC412, an inhibitor of protein kinase C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.805205

Phase I study of PKC412 (N-benzoyl-staurosporine), a novel oral protein kinase C inhibitor, combined with gemcitabine and cisplatin in patients with non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.805205

Protein kinase Cα/β inhibitor Gö6976 promotes PC12 cell adhesion and spreading through membrane recruitment and activation of protein kinase Cδ.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.805205

Effects of the selective bisindolylmaleimide protein kinase C inhibitor GF 109203X on P-glycoprotein-mediated multidrug resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.805205

Oral protein kinase c β inhibition using ruboxistaurin: efficacy, safety, and causes of vision loss among 813 patients (1,392 eyes) with diabetic retinopathy in the Protein Kinase C β Inhibitor-Diabetic Retinopathy Study and the Protein Kinase C β I

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.805205

Phase III study of gemcitabine and cisplatin with or without aprinocarsen, a protein kinase C-alpha antisense oligonucleotide, in patients with advanced-stage non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.805205

A phase I/II study of LY900003, an antisense inhibitor of protein kinase C-alpha, in combination with cisplatin and gemcitabine in patients with advanced non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.805205

Inhibitors of protein kinase C. 1. 2,3-bisarylmaleimides

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.805205

10.1517/13543776.2013.805205

21 January 2018

Identifiers

DOI

1 reference

29 August 2017

1 reference